1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Trimethylaminuria (fish-odour syndrome, fish malodour syndrome, stale fish syndrome).
1.2 OMIM# of the disease 602079.
1.3 Name of the analysed genes or DNA/chromosome segments FMO3.
OMIM# of the gene(s)
136132.
Mutational spectrum
More than 30 mutations have been reported to cause trimethylaminuria. Most are missense mutations, but nonsense mutations, small (1 or 2 bp) deletions and one large (12.2 kb) deletion, have been reported. The most common mutations identified to date are p.Pro153Leu 1 and p.Glu305X. 2 In one case, the haplotype in which a mutation occurs is important: p.Val187Ala has no effect on FMO3 activity, but when it occurs in cis with the common polymorphism p.Glu158Lys it severely affects enzyme activity. 3 A human FMO3 database has been established, 4 and causative mutations identified to date have been reported. 5, 6 In addition to rare causative mutations, 15 non-synonymous single-nucleotide polymorphic (SNP) variants of FMO3 have been identified. 7 Of these, only one, p.Asn61Lys, which occurs at low frequency, results in a severe reduction of enzyme activity. 8 However, some polymorphic variants (eg, p.Glu158Lys and p.Glu308Gly) when present in cis can cause a moderate decrease in enzyme activity. 7, 9 When present in the homozygous state, they may cause mild or transient trimethylaminuria, particularly in infants and young children, 10, 11 who have low expression of FMO3. 12 Two FMO3 haplotypes that contain promoter-region SNPs have been reported to severely reduce expression in vitro. 13 Although the impact of these haplotypes in vivo has not been validated, it is possible that they contribute to the disorder in the absence of coding-region mutations.
Analytical methods
The most common method is amplification of the eight coding exons by PCR with exon-specific primers, followed by DNA sequencing of the amplicons. Large deletions are rare, being identified in only one individual, 14 and can be identified by multiplex ligation-dependent probe amplification.
Analytical validation
Both the strands of DNA should be sequenced. Identified variants should be compared with databases and the literature to establish whether they correspond to known causative mutations. If a novel mutation is found, it is important to establish that it abolishes or substantially reduces the ability of FMO3 to catalyze the N-oxygenation of trimethylamine (TMA), as assessed by assay of heterologously expressed mutant protein. 1, 15, 16 If an individual is heterozygous for two different causative mutations, analysis of the parents' DNA will establish whether the mutations are in trans. If an individual is homozygous or compound heterozygous 17 for loss-of-function mutations of FMO3, diagnosis is confirmed.
1.8 Estimated frequency of the disease in Germany (incidence at birth ('birth prevalence') or population prevalence) For severe, inherited trimethylaminuria, the incidence of heterozygous carriers in the white British population is 0.5-1.0%. 18 The frequency of the severe type of the disorder in this population could thus be as high as 1 in 40 000. The true prevalence of the disorder is unknown; however, of patients referred to a malodour clinic in Philadelphia, 35% had trimethylaminuria. 19 1.9 If applicable, prevalence in the ethnic group of investigated person The incidence of heterozygous carriers is higher in other ethnic groups studied: 1.7% in Jordanian, 3.8% in Ecuadorian and 11.0% in New Guinean populations, 20 suggesting the frequency of the disorder may be as high as 1 in 3000 and 1 in 400 in the latter two groups, respectively.
Diagnostic setting
Comment: Trimethylaminuria usually presents with a body odour resembling that of rotten or decaying fish, the result of excess excretion of TMA in the breath, sweat, urine and reproductive fluids. [21] [22] [23] [24] 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Insufficient data to comment.
Analytical specificity (proportion of negative tests if the genotype is not present)
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Unknown. However, molecular genetic tests should distinguish between mutations that abolish or severely affect FMO3 activity and, thus, cause severe primary trimethylaminuria, from those that have a relatively moderate effect, resulting in mild or transient forms of the disorder. But acquired and secondary forms of trimethylaminuria, which are not caused by mutations, would not give a positive genetic test.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Only individuals who have tested positive for trimethylaminuria by urinary analysis, or their relatives, will be genetically tested. Note: on the basis of smell, trimethylaminuria can be difficult to distinguish from other conditions that give rise to an unpleasant body odour, including poor hygiene, forms of gingivitis and blood-borne halitosis, 29 or the rare inherited metabolic disorder dimethylglycinuria, caused by a deficiency of dimethylglycine dehydrogenase. 30 Biochemistry: diagnosis is based on the percent of total trimethylamine (free trimethylamine plus the non-odorous trimethylamine N-oxide) excreted in the urine as the unmetabolized free amine. 6, 24, 31 440%: severe trimethylaminuria. 10-39%: mild trimethylaminuria. o10%: unaffected.
Note: urinary tract infections, bacterial vaginosis, advanced liver or kidney disease and cervical cancer can 3.1.2 Describe the burden of alternative diagnostic methods to the patient Very low. However, one individual developed an adverse reaction, with fever and vomiting, after a choline challenge. 33 
How is the cost effectiveness of alternative diagnostic methods to be judged?
The initial diagnosis of trimethylaminuria is usually biochemical. Genetic testing will help to confirm the diagnosis, distinguish the various genetic and non-genetic forms of the disorder and identify asymptomatic heterozygous carriers.
Will disease management be influenced by the result of a genetic test?
(Continued )
result in large amounts of trimethylamine in the urine. But, in contrast to the inherited form of trimethylaminuria, in these cases the trimethylamine/trimethylamine N-oxide ratio is normal.
To distinguish transient or episodic forms of trimethylaminuria from the primary inherited form, biochemical testing should be performed on two separate occasions. Unaffected women may have a short episode of trimethylaminuria at the onset of and during menstruation, 26 so females should not be tested during this time.
Because of the importance of intestinal bacteria in the production of trimethylamine from dietary precursors, variations in intestinal microbiota might affect the results of the diagnostic test. Under normal dietary conditions, heterozygotes cannot be distinguished from unaffected individuals. 31 However, heterozygous carriers can be detected after administration of a 'trimethylamine load' of 600 mg, given orally in a gelatine capsule. 21, 32 No &
Yes 2 Therapy (please describe)
Strategies for treatment of the disorder 6,31 and bestpractice guidelines 23, 33 have been published. In general, the greater the effect of a mutation on the activity of FMO3, the more severe the symptoms and the less responsive the individual will be to treatment.
The main treatment strategy is dietary restriction of precursors of trimethylamine, including choline, lecithin and trimethylamine N-oxide. Choline is present in high amounts in some foods such as eggs, offal (liver, kidney), peas, beans, peanuts and soya products. Brassica vegetables (such as Brussel sprouts, broccoli, cabbage, cauliflower) are thought to inhibit FMO activity, hence, their intake should be minimized. Trimethylamine N-oxide is present in seafood. Choline is essential in the fetus and in young infants for nerve and brain development, and should not be over-restricted in infants, children and pregnant or lactating women. Nutritionally balanced, choline-restricted diets suitable for treatment of the disorder have been developed. 34 Individuals with mild or moderate forms of the disorder usually respond well.
For individuals who respond poorly to diet, a stepwise approach to other therapies should be instituted. Intermittent brief courses of antibiotics such as metronidazole (Continued )
used cautiously (eg, perimenstrually in females or for stressful social occasions) have been found to be effective. 33, 35, 36 In the case of mutations that do not completely abolish FMO3 activity, supplements of riboflavin, a precursor of the flavin adenine dinucleotide prosthetic group of FMO3, might help maximize residual enzyme activity. At present there is only anecdotal evidence of efficacy, and oral riboflavin supplementation requires careful monitoring because gastrointestinal intolerance can occur, especially in children.
Other forms of treatment are aimed at sequestering trimethylamine produced in the gut, by taking dietary supplements of copper chlorophyllin or activated charcoal. 37 Prognosis (please describe)
Affected individuals appear normal and healthy. No physical symptoms are associated with trimethylaminuria, but the unpleasant body odour characteristic of the disorder often results in social and psychological problems, 6, 21, 38 which can have serious effects on personal and working lives. These may include:
In childhood, being shunned, ridiculed or bullied at school, leading to aggressive or disruptive behaviour and poor educational performance.
A sense of shame or embarrassment, leading to low self-esteem and reluctance to seek medical help.
Avoidance of contact with people, leading to social isolation, loneliness, frustration and depression.
Difficulties in initiating or maintaining relationships. In extreme cases, paranoid behaviour, desperation and suicidal tendencies.
For individuals with primary genetic trimethylaminuria, symptoms are usually present from birth.
The condition may worsen during puberty and, in females, is more severe just before and during menstruation, after taking oral contraceptives and around menopause. Treatment and dietary management may alleviate symptoms in some, but not all, individuals. Management (please describe) Affected individuals should avoid:
1. Foods with a high content of precursors of trimethylamine or inhibitors of FMO3 activity, for instance, eggs, offal (liver and kidney), legumes, Brassicas, soya products and seafood (fish, crustaceans and cephalopods), should be avoided or eaten in moderation. Freshwater fish are not a problem.
2. Drugs that are metabolized by FMO3, which will exacerbate the condition by competition for residual FMO3 activity and may cause adverse effects. Examples include the antipsychotic clozapine, the monoamine oxidase inhibitor deprenyl, the anti-histamine ranitidine, the anti-oestrogen tamoxifen and the anti-inflammatories sulindac and benzydamine. 7 3. Food supplements and 'health' foods that contain high amounts of choline and lecithin. 4. Factors that promote sweating, such as fever, exercise, stress and emotional upsets. Trimethylamine is a strong base (pKa 9.8). Thus, at pH 6.0, o0.02% of trimethylamine exists as the volatile free base. The use of soaps and body lotions with a pH close to that of normal skin (pH 5.5-6.5) helps to retain secreted trimethylamine in a less volatile salt form that can be removed by washing. 39 Yes, but it is not indicated.
Predictive
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Affected individuals and their families benefit from counselling. Realization that the problem is the result of a recognized medical condition may help.
